期刊
LEUKEMIA & LYMPHOMA
卷 49, 期 12, 页码 2246-2255出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428190802510349
关键词
AML; FLT3 mutations; MAP kinase signalling; sorafenib
资金
- Bayer/Onyx
- NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER
The identification of aberrant cellular pathways and dysfunctional molecules important in neoplastic transformation has begun to provide us with a number of targets for drug development. It is likely that many of these agents will be incorporated into our existing treatment strategies that include cytotoxic agents. Sorafenib, a multi-kinase inhibitor has been approved in the United States for the treatment of renal cell carcinoma as well as hepatocellular cancer. Its potential role in hematological malignancies, particularly acute myeloid leukemia (AML) is under evaluation. Here we describe the biological pathways in AML that are the potential targets of sorafenib action and discuss the early clinical data with the agent in solid tumors and AML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据